EN DE

Winning Health Technology Group (300253) Fair Value & Analysis

Healthcare · CN · Market cap 15.9B CNY

WH Winning Health Technology Group 300253 · SHE
Price¥7.76
Fair Value¥1.18
Upside-84.8%
Quality47/100
Watch Winning Health Technology Group for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Loss-making · -16.9% net margin
Low debt · generates free cash flow
Trails peers (4/11)
Narrow moat 15/100
Evidence: Medium Range ¥0.9100 – ¥1.45 Share as image

Fair value as of: Jul 9, 2026

From 12 valuation models · updated 32 days ago

Fair value updated Jul 9, 2026, revised from ¥2.08 to ¥1.18 (−43.3%) since Jun 24, 2026. Share price +18.7% over the past month.

Below-average quality, and screening another 85% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (¥1.45). The favourable scenario is already priced in.
  • Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

¥18.76 ¥5.14 Fair Value ¥1.18 Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.

How to read this chart

60‑month range ¥5.14 – ¥18.76 · fair‑value band ¥0.9100 – ¥1.45 · the ¥7.76 price screens above the ¥1.18 fair value. Dashed = 300-day average. As of Jul 9, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Winning Health Technology Group (300253) currently trades at ¥7.76, while our model-based Fair Value estimate is ¥1.18, implying the stock looks roughly 84.8% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Winning Health Technology Group generated revenue of 2.2B CNY at a net margin of -16.9%. Revenue grew 15.2% year over year. It earns a return on equity of -6.6%. The balance sheet holds a net cash position of 230M CNY. Fundamentals as of Jul 9, 2026

Our scenario range runs from ¥0.9100 (bear case) to ¥1.45 (bull case); at ¥7.76, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 52% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -85%, 300253 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF ¥2.42 ¥4.63 ¥8.14 80
Rev-Margin DCF ¥1.94 ¥3.27 ¥5.13 74
Gordon GGM ¥0.2000 ¥0.4200 ¥0.6700 70
All 12 models by family
DCF Models
FCF DCF ¥2.48 ¥4.33 ¥9.01 38
5Y Revenue Exit ¥1.94 ¥3.32 ¥5.27 39
5Y EBITDA Exit ¥1.49 ¥2.32 ¥3.36 41
10Y Revenue Exit ¥2.05 ¥3.48 ¥5.85 36
10Y EBITDA Exit ¥1.79 ¥2.70 ¥4.13 37
Dividend Discount
Gordon GGM ¥0.2000 ¥0.4200 ¥0.6700 70
DDM Multi-Stage ¥0.2000 ¥0.3600 ¥0.4400 61
Multiples
EV/EBITDA ¥1.11 ¥1.38 ¥1.65 54
EV/Revenue ¥1.68 ¥2.28 ¥2.87 43
Asset-Based
NCAV (Graham) ¥1.27 ¥1.70 ¥2.54 50
Growth DCF
Growth DCF ¥2.42 ¥4.63 ¥8.14 80
Rev-Margin DCF ¥1.94 ¥3.27 ¥5.13 74

Widest divergence: DCF Models (¥3.32) versus Dividend Discount (¥0.3600). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) 2.2B CNY
Revenue growth (YoY) +15.2%
Net margin -16.9%
Return on equity -6.6%
Free cash flow 335M CNY FY2025
Operating margin -0.2%
More key figures
EPS (TTM) ¥-0.1600
EPS growth (YoY) +163%
Net cash 230M CNY FY2024

Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 47/100

Of which business quality 51 · Market factors (momentum, volatility) 26

Profitability 5
Margins and returns on capital today
Quality Growth 11
Are margins and returns improving?
Cashflow 67
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 75
Disciplined investing over empire-building
Low Volatility 58
Calm price path (market factor)
Momentum 15
Price trend over the last 3–12 months (market factor)
52W Momentum 10
Distance to the 52-week high (market factor)
Net Issuance 62
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Winning Health Technology Group Co., Ltd., together with its subsidiaries, provides digital health services for medical and health institutions in China. The company offers WiNEX, a digital health platform; internet and health care; smart hospital; smart regional healthcare; and WinCloud solutions.

Full company description

Winning Health Technology Group Co., Ltd., together with its subsidiaries, provides digital health services for medical and health institutions in China. The company offers WiNEX, a digital health platform; internet and health care; smart hospital; smart regional healthcare; and WinCloud solutions. Its solutions are used in smart hospitals, regional health, public health, medical insurance, health services, and other fields. The company is involved in general items; software development; information system operation and maintenance; investment; non-residential real estate leasing; technology development, transfer, and promotion; and medical device sale. In addition, it provides computer hardware, software, and peripherals; information technology consulting; internet data; technical consulting; and technical services. The company was formerly known as Shanghai Kingstar Winning Software Co., Ltd. and changed its name to Winning Health Technology Group Co., Ltd. in January 2016. Winning Health Technology Group Co., Ltd. was founded in 1994 and is headquartered in Shanghai, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Winning Health Technology Group reported revenue of ¥2.1B in FY2025 versus ¥2.8B in FY2021, a compound −6.5%/yr. Reported net income was −¥374M in FY2025.

Growth Quality 24/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
2.1B CNY
Latest YoY
−24.3%
Avg. growth/yr (3Y)
−12.0%
Avg. growth/yr (5Y)
−1.5%
Avg. growth/yr (18Y)
+22.8%
Revenue −6.5%/yr
FY21 ¥2.8B
FY22 ¥3.1B
FY23 ¥3.2B
FY24 ¥2.8B
FY25 ¥2.1B
Net income
FY21 ¥378M
FY22 ¥109M
FY23 ¥358M
FY24 ¥87.9M
FY25 −¥374M

300253 screens 85% overvalued. Compare with Veeva Systems Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Winning Health Technology Group Fair Value". https://www.fairvalue-calculator.com/stock/300253

Peer Group

Health Information Services · 127 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 47 · Below median
Fair Value upside −85% · Bottom 25%
Return on assets -2% · Below median
Net margin (TTM) -17% · Bottom 25%
Operating margin (TTM) -0% · Below median
Revenue growth 15% · Above median
Debt / equity 0.20× · Higher than median

Valuation Multiples vs Health Information Services median · lower = cheaper

P/B 0.42× · Cheaper than 75% of peers
P/S (TTM) 1.09× · Cheaper than median
P/FCF 7.0× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 76 · sector 33
PAST 0 · sector 7
HEALTH 90 · sector 98
DIVIDEND 0 · sector 35

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $190.12 $95.12 -50%
Pro Medicus Limited PME A$194.84 A$23.74 -88%
BrightSpring Health Services, Inc BTSG $68.16 $21.31 -69%
HealthEquity, Inc HQY $97.67 $56.63 -42%
Hinge Health, Inc HNGE $88.80 $24.03 -73%
10x Genomics, Inc TXG $45.75 $17.18 -62%
Waystar Holding WAY $22.69 $12.86 -43%
Doximity, Inc DOCS $22.21 $17.18 -23%
Privia Health Group PRVA $28.10 $5.30 -81%
Inventurus Knowledge Solutions Limited IKS ₹1,846 ₹860.28 -53%

Compare Winning Health Technology Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Winning Health Technology Group (300253) overvalued or undervalued?
As of Jul 9, 2026, our model estimates a fair value of ¥1.18 versus a price of ¥7.76, about −85% (overvalued).
What is the fair value of 300253?
Our model-based fair value for Winning Health Technology Group is ¥1.18 (as of Jul 9, 2026), built from audited fundamentals. The current price is ¥7.76.
What is the quality score of 300253?
Winning Health Technology Group has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Winning Health Technology Group (300253)?
Winning Health Technology Group reported trailing-twelve-month revenue of about 2.2B CNY (latest available figure, as of Jul 9, 2026).
What is the net profit margin of 300253?
The net profit margin of Winning Health Technology Group is about -16.9%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Winning Health Technology Group and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.